Clinical Trials Directory

Trials / Completed

CompletedNCT01500681

Maintenance Plasma Exchange for Neuromyelitis Optica

A Prospective Observational Study of Maintenance Plasma Exchange (PLEX) for Neuromyelitis Optica Spectrum Disorders (MultiPLEX Study)

Status
Completed
Phase
Study type
Observational
Enrollment
9 (actual)
Sponsor
Mayo Clinic · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Neuromyelitis optica (NMO) is an inflammatory disease of the central nervous system that is associated with autoantibodies to aquaporin-4. Treatment options for prevention of clinical relapses of NMO include immunosuppressive medications. Plasma exchange (PLEX) is commonly used as a rescue therapy for NMO relapses but ongoing, regular PLEX procedures (maintenance PLEX) is sometimes used to prevent relapses. This observational registry will record feasibility, tolerability, safety, and preliminary efficacy data regarding maintenance PLEX for NMO.

Detailed description

Neuromyelitis optica (NMO) is an inflammatory disease of the central nervous system that is associated with autoantibodies to aquaporin-4. Treatment options for prevention of clinical relapses of NMO include immunosuppressive medications. Plasma exchange (PLEX) is commonly used as a rescue therapy for NMO relapses but ongoing, regular PLEX procedures (maintenance PLEX) is sometimes used to prevent relapses. This observational registry will record feasibility, tolerability, safety, and preliminary efficacy data regarding maintenance PLEX for participants with NMO, NMO spectrum disorders, and recurrent idiopathic longitudinally extensive transverse myelitis.

Conditions

Interventions

TypeNameDescription
PROCEDUREPlasma exchange (PLEX)Regular maintenance PLEX courses, typically 3 procedures monthly

Timeline

Start date
2012-06-01
Primary completion
2015-07-09
Completion
2015-07-09
First posted
2011-12-28
Last updated
2021-12-27

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01500681. Inclusion in this directory is not an endorsement.